PE20020533A1 - Kit de repinotano - Google Patents
Kit de repinotanoInfo
- Publication number
- PE20020533A1 PE20020533A1 PE2001001162A PE2001001162A PE20020533A1 PE 20020533 A1 PE20020533 A1 PE 20020533A1 PE 2001001162 A PE2001001162 A PE 2001001162A PE 2001001162 A PE2001001162 A PE 2001001162A PE 20020533 A1 PE20020533 A1 PE 20020533A1
- Authority
- PE
- Peru
- Prior art keywords
- repinotane
- kit
- blood
- refers
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
SE REFIERE A UN KIT QUE COMPRENDE: a) UNA COMPOSICION FARMACEUTICA QUE CONTIENE HIDROCLORURO DE REPINOTANO 1,1-DIOXIDO DE 2-[4-({[(2R)-CROMAN-2-IL]METIL}AMINO)BUTIL]-1,2-BENCISOTIAZOL-3(2H)-ONA Y b) UN MEDIO PARA DETERMINAR LA CONCENTRACION DE REPINOTANO O SUS METABOLITOS EN LIQUIDOS CORPORALES. SE REFIERE TAMBIEN A UN MEDIO PARA DETERMINAR LA CONCENTRACION DEL AGENTE ANALITICO EN LA SANGRE, EN FRACCIONES DE SANGRE, EN PLASMA SANGUINEO. LA COMPOSICION SOLIDA CONTIENE ENTRE 0,01% A 15% EN PESO DE SUSTANCIA ACTIVA Y DE 0,5% Y 15 % EN PESO DEL ACIDO. EL KIT DE REPINOTANO ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10058119A DE10058119A1 (de) | 2000-11-22 | 2000-11-22 | Pepinotan-Kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020533A1 true PE20020533A1 (es) | 2002-07-13 |
Family
ID=7664358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001162A PE20020533A1 (es) | 2000-11-22 | 2001-11-21 | Kit de repinotano |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US6605255B2 (es) |
| EP (1) | EP1339403B1 (es) |
| JP (2) | JP2004517824A (es) |
| KR (1) | KR20030096237A (es) |
| CN (2) | CN1715279A (es) |
| AR (1) | AR031761A1 (es) |
| AT (1) | ATE284212T1 (es) |
| AU (1) | AU2002227912A1 (es) |
| BG (1) | BG107803A (es) |
| BR (1) | BR0115518A (es) |
| CA (1) | CA2429310A1 (es) |
| CZ (1) | CZ20031401A3 (es) |
| DE (2) | DE10058119A1 (es) |
| DO (1) | DOP2001000293A (es) |
| EC (1) | ECSP034617A (es) |
| EE (1) | EE200300242A (es) |
| ES (1) | ES2234922T3 (es) |
| GT (1) | GT200100236A (es) |
| HN (1) | HN2001000262A (es) |
| HR (1) | HRP20030490A2 (es) |
| HU (1) | HUP0303294A2 (es) |
| IL (1) | IL155975A0 (es) |
| MA (1) | MA26059A1 (es) |
| MX (1) | MXPA03004499A (es) |
| MY (1) | MY118345A (es) |
| NO (1) | NO20032212D0 (es) |
| NZ (1) | NZ525964A (es) |
| PE (1) | PE20020533A1 (es) |
| PL (1) | PL361628A1 (es) |
| PT (1) | PT1339403E (es) |
| RU (1) | RU2003118583A (es) |
| SI (1) | SI1339403T1 (es) |
| SK (1) | SK5922003A3 (es) |
| SV (1) | SV2003000744A (es) |
| UY (1) | UY27027A1 (es) |
| WO (1) | WO2002041881A2 (es) |
| ZA (1) | ZA200303888B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004010050A1 (de) * | 2004-03-02 | 2005-09-22 | Bayer Healthcare Ag | Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US8329695B2 (en) * | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| DE19522088A1 (de) * | 1995-06-19 | 1997-01-02 | Bayer Ag | Benzisothiazolyl-substituierte Aminomethylchromane |
| DE19543476A1 (de) * | 1995-11-22 | 1997-05-28 | Troponwerke Gmbh & Co Kg | Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| DE19754573A1 (de) * | 1997-12-09 | 1999-06-10 | Bayer Ag | Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma |
| WO1999046591A2 (en) * | 1998-03-10 | 1999-09-16 | Strategic Diagnostics, Inc. | Integrated assay device and methods of production and use |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| DE19936281C2 (de) | 1999-08-02 | 2002-04-04 | Bayer Ag | Verfahren zur Gefriertrocknung |
-
2000
- 2000-11-22 DE DE10058119A patent/DE10058119A1/de not_active Ceased
-
2001
- 2001-11-09 BR BR0115518-0A patent/BR0115518A/pt not_active IP Right Cessation
- 2001-11-09 AU AU2002227912A patent/AU2002227912A1/en not_active Abandoned
- 2001-11-09 SI SI200130270T patent/SI1339403T1/xx unknown
- 2001-11-09 HU HU0303294A patent/HUP0303294A2/hu unknown
- 2001-11-09 CA CA002429310A patent/CA2429310A1/en not_active Abandoned
- 2001-11-09 CZ CZ20031401A patent/CZ20031401A3/cs unknown
- 2001-11-09 RU RU2003118583/15A patent/RU2003118583A/ru not_active Application Discontinuation
- 2001-11-09 EE EEP200300242A patent/EE200300242A/xx unknown
- 2001-11-09 CN CNA2005100859302A patent/CN1715279A/zh active Pending
- 2001-11-09 SK SK592-2003A patent/SK5922003A3/sk unknown
- 2001-11-09 PT PT01989448T patent/PT1339403E/pt unknown
- 2001-11-09 EP EP01989448A patent/EP1339403B1/de not_active Expired - Lifetime
- 2001-11-09 MX MXPA03004499A patent/MXPA03004499A/es unknown
- 2001-11-09 KR KR10-2003-7006854A patent/KR20030096237A/ko not_active Application Discontinuation
- 2001-11-09 NZ NZ525964A patent/NZ525964A/en unknown
- 2001-11-09 WO PCT/EP2001/012968 patent/WO2002041881A2/de not_active Application Discontinuation
- 2001-11-09 DE DE2001504790 patent/DE50104790D1/de not_active Expired - Fee Related
- 2001-11-09 PL PL36162801A patent/PL361628A1/xx not_active Application Discontinuation
- 2001-11-09 CN CNA018221440A patent/CN1518446A/zh active Pending
- 2001-11-09 JP JP2002544060A patent/JP2004517824A/ja active Pending
- 2001-11-09 IL IL15597501A patent/IL155975A0/xx unknown
- 2001-11-09 ES ES01989448T patent/ES2234922T3/es not_active Expired - Lifetime
- 2001-11-09 AT AT01989448T patent/ATE284212T1/de not_active IP Right Cessation
- 2001-11-16 US US09/991,222 patent/US6605255B2/en not_active Expired - Fee Related
- 2001-11-19 UY UY27027A patent/UY27027A1/es not_active Application Discontinuation
- 2001-11-20 MY MYPI20015310A patent/MY118345A/en unknown
- 2001-11-20 AR ARP010105412A patent/AR031761A1/es unknown
- 2001-11-21 SV SV2001000744A patent/SV2003000744A/es unknown
- 2001-11-21 HN HN2001000262A patent/HN2001000262A/es unknown
- 2001-11-21 PE PE2001001162A patent/PE20020533A1/es not_active Application Discontinuation
- 2001-11-21 DO DO2001000293A patent/DOP2001000293A/es unknown
- 2001-11-22 GT GT200100236A patent/GT200100236A/es unknown
-
2003
- 2003-05-12 BG BG107803A patent/BG107803A/bg unknown
- 2003-05-15 NO NO20032212A patent/NO20032212D0/no not_active Application Discontinuation
- 2003-05-20 ZA ZA200303888A patent/ZA200303888B/en unknown
- 2003-05-21 EC EC2003004617A patent/ECSP034617A/es unknown
- 2003-05-22 MA MA27170A patent/MA26059A1/fr unknown
- 2003-05-22 US US10/444,820 patent/US20030203953A1/en not_active Abandoned
- 2003-06-17 HR HR20030490A patent/HRP20030490A2/hr not_active Application Discontinuation
-
2005
- 2005-04-26 JP JP2005128270A patent/JP2005232189A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020533A1 (es) | Kit de repinotano | |
| ES2178153T3 (es) | Una mezcla estsabilizada que comprende fibrinogeno. | |
| DE50211045D1 (de) | Medizinische aerosolformulierungen | |
| EA200501702A1 (ru) | Устойчивая к манипуляциям дозировочная форма для трансдермального введения | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| BR9909565A (pt) | Derivados bicìclicos do ácido hidroxâmico | |
| SV1996000109A (es) | Nueva variante cristalina del cdch, procedimiento para su produccion y preparados farmaceuticos que la contienen ref. lea 31308-sv | |
| SV2006002174A (es) | Composicion de anticuerpo her2 | |
| AR043144A1 (es) | Formulacion de inmunoglobulina y metodo de preparacion de la misma | |
| BR0311877A (pt) | Preparações ácidas de insulina com estabilidade aperfeiçoada | |
| CY1110316T1 (el) | Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους | |
| MY162068A (en) | Formulation of human antibodies for treating tnf-(alpha) associated disorders | |
| HUP0202889A2 (en) | Method and sensor for measuring the concentration of an analyte in an ocular fluid | |
| MXPA02006679A (es) | Composicion farmaceutica. | |
| MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
| EE05054B1 (et) | 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis | |
| EA200201044A1 (ru) | Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин | |
| EP1663201A4 (en) | USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| EA200970239A1 (ru) | Режим титрования бифепрунокса для лечения шизофрении и наборы для применения в этой области | |
| MA30600B1 (fr) | Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique. | |
| CY1110659T1 (el) | Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος | |
| SE0402284D0 (sv) | New heterocyclic amides | |
| MA27731A1 (fr) | Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete | |
| SE0203753D0 (sv) | New compounds | |
| DE60225587D1 (de) | Protease assay zur kontrolle medikamentöser therapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |